{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:10:10Z","timestamp":1770743410892,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"DOI":"10.7759\/cureus.103309","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:26:08Z","timestamp":1770683168000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic Utility of PRAME and SOX10 Immunostaining for Vulvar Melanocytic Lesions"],"prefix":"10.7759","author":[{"given":"Kridtin","family":"Jarutatsanangkoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phitsinee","family":"Purngpiputtrakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchanan","family":"Hanamornroongruang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuthinun","family":"Achariyapota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panitta","family":"Sitthinamsuwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(92)91623-i","article-title":"In situ and invasive vulvar cancer incidence trends (1973 to 1987)","volume":"166","author":"Sturgeon SR","year":"1992","unstructured":"Sturgeon SR, Brinton LA, Devesa SS, Kurman RJ. In situ and invasive vulvar cancer incidence trends (1973 to 1987). Am J Obstet Gynecol. 1992, 166:1482-5. 10.1016\/0002-9378(92)91623-i","journal-title":"Am J Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2018.07.011","article-title":"Melanoma of the vulva and vagina: Surgical management and outcomes based on a clinicopathologic review of 68 cases","volume":"41","author":"Sinasac SE","year":"2019","unstructured":"Sinasac SE, Petrella TM, Rouzbahman M, Sade S, Ghazarian D, Vicus D. Melanoma of the vulva and vagina: Surgical management and outcomes based on a clinicopathologic review of 68 cases. J Obstet Gynaecol Can. 2019, 41:762-71. 10.1016\/j.jogc.2018.07.011","journal-title":"J Obstet Gynaecol Can"},{"key":"ref3","article-title":"Melanomas of the vulva and vagina","volume":"64","author":"Skovsted S","year":"2017","unstructured":"Skovsted S, Nielsen K, Blaakaer J. Melanomas of the vulva and vagina. Dan Med J. 2017, 64:5336.","journal-title":"Dan Med J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant melanoma of the vulva and vagina: A US population-based study of 1863 patients","volume":"21","author":"Wohlmuth C","year":"2020","unstructured":"Wohlmuth C, Wohlmuth-Wieser I, May T, Vicus D, Gien LT, Laframboise S. Malignant melanoma of the vulva and vagina: A US population-based study of 1863 patients. Am J Clin Dermatol. 2020, 21:285-95. 10.1007\/s40257-019-00487-x","journal-title":"Am J Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930301)71:5<1893::aid-cncr2820710528>3.0.co;2-7","article-title":"Malignant melanoma of the vulva and vagina: Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960-1984","volume":"71","author":"Ragnarsson-Olding B","year":"1993","unstructured":"Ragnarsson-Olding B, Johansson H, Rutqvist LE, Ringborg U. Malignant melanoma of the vulva and vagina: Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960-1984. Cancer. 1993, 71:1893-7. 10.1002\/1097-0142(19930301)71:5&lt;1893::aid-cncr2820710528&gt;3.0.co;2-7","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1273::AID-CNCR24>3.0.CO;2-Z","article-title":"Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: Clinical observations and histopathologic features","volume":"86","author":"Ragnarsson-Olding BK","year":"1999","unstructured":"Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlof B, Nilsson BR, Ringborg UK . Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: Clinical observations and histopathologic features. Cancer. 1999, 86:24-3. 10.1002\/(SICI)1097-0142(19991001)86:7&lt;1273::AID-CNCR24&gt;3.0.CO;2-Z","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/93.6.731","article-title":"Morphologic diversity in malignant melanomas","volume":"93","author":"Nakhleh RE","year":"1990","unstructured":"Nakhleh RE, Wick MR, Rocamora A, Swanson PE, Dehner LP. Morphologic diversity in malignant melanomas. Am J Clin Pathol. 1990, 93:731-40. 10.1093\/ajcp\/93.6.731","journal-title":"Am J Clin Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.02.028","article-title":"Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy","volume":"129","author":"Janco JM","year":"2013","unstructured":"Janco JM, Markovic SN, Weaver AL, Cliby WA. Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. Gynecol Oncol. 2013, 129:533-7. 10.1016\/j.ygyno.2013.02.028","journal-title":"Gynecol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1285::AID-CNCR25>3.0.CO;2-P","article-title":"Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: Predictors of survival","volume":"86","author":"Ragnarsson-Olding BK","year":"1999","unstructured":"Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR, Lagerlof B, Ringborg UK. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: Predictors of survival. Cancer. 1999, 86:25-3. 10.1002\/(SICI)1097-0142(19991001)86:7&lt;1285::AID-CNCR25&gt;3.0.CO;2-P","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2019.1870","article-title":"An updated review of mucosal melanoma: Survival meta-analysis","volume":"11","author":"Hahn HM","year":"2019","unstructured":"Hahn HM, Lee KG, Choi W, Cheong SH, Myung KB, Hahn HJ. An updated review of mucosal melanoma: Survival meta-analysis. Mol Clin Oncol. 2019, 11:116-26. 10.3892\/mco.2019.1870","journal-title":"Mol Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2001.01043.x","article-title":"Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later","volume":"11","author":"Verschraegen CF","year":"2001","unstructured":"Verschraegen CF, Benjapibal M, Supakarapongkul W, et al.. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer. 2001, 11:359-64. 10.1046\/j.1525-1438.2001.01043.x","journal-title":"Int J Gynecol Cancer"},{"key":"ref12","article-title":"The risk of melanoma and neurocutaneous melanosis associated with congenital melanocytic nevi","volume":"29","author":"Shah KN","year":"2010","unstructured":"Shah KN. The risk of melanoma and neurocutaneous melanosis associated with congenital melanocytic nevi. Semin Cutan Med Surg. 2010, 29:159-64.","journal-title":"Semin Cutan Med Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9554.1000160","article-title":"Clinical and histopathological characteristics of genital melanocytic nevi: A report of 109 cases and a review of the literature","volume":"3","author":"Yarak S","year":"2012","unstructured":"Yarak S, Michalany NS, Heinke T, et al.. Clinical and histopathological characteristics of genital melanocytic nevi: A report of 109 cases and a review of the literature. J Clin Exp Dermatol Res. 2012, 3:5-10. 10.4172\/2155-9554.1000160","journal-title":"J Clin Exp Dermatol Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e318279bc0a","article-title":"SOX10 expression in malignant melanoma, carcinoma, and normal tissues","volume":"21","author":"Mohamed A","year":"2013","unstructured":"Mohamed A, Gonzalez RS, Lawson D, Wang J, Cohen C. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol. 2013, 21:506-10. 10.1097\/PAI.0b013e318279bc0a","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283403ccd","article-title":"SOX10 expression in superficial spreading and nodular malignant melanomas","volume":"20","author":"Agnarsd\u00f3ttir M","year":"2010","unstructured":"Agnarsd\u00f3ttir M, Sooman L, Bolander A, et al.. SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Res. 2010, 20:468-78. 10.1097\/CMR.0b013e3283403ccd","journal-title":"Melanoma Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e318297a9d0","article-title":"Value of SOX10 immunostaining in tumor diagnosis","volume":"20","author":"Ord\u00f3\u00f1ez NG","year":"2013","unstructured":"Ord\u00f3\u00f1ez NG. Value of SOX10 immunostaining in tumor diagnosis. Adv Anat Pathol. 2013, 20:275-83. 10.1097\/PAP.0b013e318297a9d0","journal-title":"Adv Anat Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2021.01.001","article-title":"PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions","volume":"14","author":"Lezcano C","year":"2021","unstructured":"Lezcano C, Jungbluth AA, Busam KJ. PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions. Surg Pathol Clin. 2021, 14:165-75. 10.1016\/j.path.2021.01.001","journal-title":"Surg Pathol Clin"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano C","year":"2018","unstructured":"Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME expression in melanocytic tumors. Am J Surg Pathol. 2018, 42:1456-65. 10.1097\/PAS.0000000000001134","journal-title":"Am J Surg Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001492","article-title":"Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors","volume":"44","author":"Lezcano C","year":"2020","unstructured":"Lezcano C, Jungbluth AA, Busam KJ. Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors. Am J Surg Pathol. 2020, 44:893-900. 10.1097\/PAS.0000000000001492","journal-title":"Am J Surg Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2021.12.008","article-title":"Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation","volume":"121","author":"Fattori A","year":"2022","unstructured":"Fattori A, de la Fouchardi\u00e8re A, Cribier B, Mitcov M. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation. Hum Pathol. 2022, 121:19-28. 10.1016\/j.humpath.2021.12.008","journal-title":"Hum Pathol"},{"key":"ref21","article-title":"Melanocytic neoplasms","author":"Bastian BC","year":"2020","unstructured":"Bastian BC, Lazar AJ, Scolyer RA, et al.. Melanocytic neoplasms. Skin Tumours. nternational Agency for Research on Cancer, Lyon, France; 2020. 12:512."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4103\/ijmpo.ijmpo_84_16","article-title":"Round cell tumors: Classification and immunohistochemistry","volume":"38","author":"Sharma S","year":"2017","unstructured":"Sharma S, Kamala R, Nair D, et al.. Round cell tumors: Classification and immunohistochemistry. Indian J Med Paediatr Oncol. 2017, 38:349-53. 10.4103\/ijmpo.ijmpo_84_16","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2007.00891.x","article-title":"Immunohistochemical characteristics of melanoma","volume":"35","author":"Ohsie SJ","year":"2008","unstructured":"Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008, 35:433-44. 10.1111\/j.1600-0560.2007.00891.x","journal-title":"J Cutan Pathol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/his.14904","article-title":"Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions","volume":"83","author":"Kunc M","year":"2023","unstructured":"Kunc M, \u017bemierowska N, Skowronek F, Biernat W. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions. Histopathology. 2023, 83:3-14. 10.1111\/his.14904","journal-title":"Histopathology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000972","article-title":"HMB45\/PRAME, a novel double staining for the diagnosis of melanocytic neoplasms: technical aspects, results, and comparison with other commercially available staining (PRAME and Melan A\/PRAME)","volume":"30","author":"Grillini M","year":"2022","unstructured":"Grillini M, Ricci C, Pino V, Pedrini S, Fiorentino M, Corti B. HMB45\/PRAME, a novel double staining for the diagnosis of melanocytic neoplasms: technical aspects, results, and comparison with other commercially available staining (PRAME and Melan A\/PRAME). Appl Immunohistochem Mol Morphol. 2022, 30:14-8. 10.1097\/PAI.0000000000000972","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2021.11.002","article-title":"Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi","volume":"120","author":"Hu J","year":"2022","unstructured":"Hu J, Cai X, Lv JJ, et al.. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi. Hum Pathol. 2022, 120:9-17. 10.1016\/j.humpath.2021.11.002","journal-title":"Hum Pathol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/his.14312","article-title":"PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna","volume":"78","author":"Gradecki SE","year":"2021","unstructured":"Gradecki SE, Valdes-Rodriguez R, Wick MR, Gru AA. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology. 2021, 78:1000-8. 10.1111\/his.14312","journal-title":"Histopathology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450971-diagnostic-utility-of-prame-and-sox10-immunostaining-for-vulvar-melanocytic-lesions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:26:09Z","timestamp":1770683169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450971-diagnostic-utility-of-prame-and-sox10-immunostaining-for-vulvar-melanocytic-lesions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.103309","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}